Search results
Results from the WOW.Com Content Network
Poliomyelitis (/ ˌ p oʊ l i oʊ ˌ m aɪ ə ˈ l aɪ t ɪ s / POH-lee-oh-MY-ə-LY-tiss), commonly shortened to polio, is an infectious disease caused by the poliovirus. [1] Approximately 75% of cases are asymptomatic; [5] mild symptoms which can occur include sore throat and fever; in a proportion of cases more severe symptoms develop such as headache, neck stiffness, and paresthesia.
Post-polio syndrome (PPS, poliomyelitis sequelae) is a group of latent symptoms of poliomyelitis (polio), occurring in more than 80% of polio infections. The symptoms are caused by the damaging effects of the viral infection on the nervous system and typically occur 15 to 30 years after an initial acute paralytic attack.
Polioencephalitis is a viral infection of the brain, causing inflammation within the grey matter of the brain stem. [1] The virus has an affinity for neuronal cell bodies and has been found to affect mostly the midbrain, pons, medulla and cerebellum of most infected patients.
List of Antiviral Drugs Antiviral Use Manufacturer Component Type Year approved Abacavir: HIV: ViiV Healthcare: Nucleoside analogue reverse transcriptase inhibitor (NRTI) 1998 Acyclovir (Aciclovir) Herpes Simplex, chickenpox, [2] varicella zoster virus: GSK: guanosine analogue RTI 1981 Adefovir: Hepatitis B [3] Gilead Sciences RTI 2002 , 2003 ...
The distinct speciation of poliovirus probably occurred as a result of a change in cellular receptor specificity from intercellular adhesion molecule-1 (ICAM-1) (used by C-cluster Coxsackie A viruses) to CD155, leading to a change in pathogenicity and allowing the virus to infect nerve tissue. The mutation rate in the virus is relatively high ...
A few could contract meningitis if the polio virus attacks the covering of the spinal cord or brain. Polio is fatal for 2%-10% of those paralyzed or between 1 in 2,000 to 1 in 10,000 of those ...
Non-polio enteroviruses, like EV-D68, cause about 10 to 15 million infections and tens of thousands of hospitalizations each year across the US. EV-D68 was first identified in California in the ...
The drug has a relatively intermediate duration of action when compared to other non-depolarizing agents. [2] The drug has an onset of 2 to 3 minutes in adults and an expected peak effect at 3 to 5 minutes. [2] Recovery is expected to begin within 20 to 35 minutes of the initial dose, but it may take up to 70 minutes to achieve 95% recovery. [2]